Budesonide–formoterol (inhalation powder) in the treatment of COPD by Ceylan, Erkan
International Journal of COPD 2006:1(2) 115–122
© 2006 Dove Medical Press Limited. All rights reserved
115
REVIEW
Budesonide–formoterol (inhalation powder) 
in the treatment of COPD
Erkan Ceylan
Harran University, Faculty 
of Medicine, Department of Chest 
Diseases, Sanliurfa, Turkey
Correspondence: Erkan Ceylan
Yenisehir 8. Sk. Cemalgüllüoglu apt.D: 11, 
63300 Sanliurfa, Turkey
Tel + 90 4 14314 117 02199
Fax + 90 4 14315 1181
Email drerkanceylan@yahoo.com
Abstract: The budesonide–formoterol dry powder inhaler (Symbicort® Turbuhaler® 
160/4.5–640/18 μg/day) contains the long-acting β2-adrenoreceptor agonist formoterol and 
the inhaled corticosteroid budesonide. Two large, 12-month trials examined the effect of 
budesonide–formoterol 160/4.5 μg twice daily in COPD patients who met these criteria. The 
studies were identical, except one in which the patients had received oral prednisolone 30 mg/day 
and had inhaled formoterol 4.5 μg twice daily for 2 weeks before randomization. In terms of the 
FEV1, budesonide–formoterol produced an effect greater than that of both budesonide alone and 
formoterol alone reported in previous studies. The combination was generally more effective 
than either of the components in terms of peak expiratory ﬂ  ow, symptoms, and exacerbations. 
These advantages of the combination over those of either budesonide alone or formoterol 
alone were quite consistent. Improving lung function and decreasing symptoms signiﬁ  cantly, 
budesonide–formoterol combination therapy provides signiﬁ  cant clinical improvements in 
COPD, despite the limited reversibility of impaired lung function in the disease.
Keywords: chronic obstructive lung disease, budesonide–formoterol, budesonide, formoterol, 
combination therapy, dry powder inhalation
Introduction
COPD is an important cause of morbidity, mortality, and hospital admissions. This 
disorder is characterized by airﬂ  ow limitation that is not fully reversible despite 
bronchodilator therapy. This limitation in airﬂ  ow, which is associated with an exag-
gerated inﬂ  ammatory response of the lung to the inhalation of noxious particles or 
gases, usually worsens progressively (Pauwels et al 2001; Fabbri and Hurd 2003; 
NHLBI/WHO workshop report 2004).
COPD is a multicomponent disease that includes airway inﬂ  ammation, airﬂ  ow 
limitation, mucociliary dysfunction, and airway structural changes (Pauwels et al 
2001). Oxidative stress and an imbalance between proteases and antiproteases in the 
lung have also been implicated in the pathophysiology of the condition (Barnes 2000a). 
All COPD components contribute to a complex of lung function changes, symptoms, 
and exacerbations, which affect the patient’s health and, ultimately, survival (Pauwels 
et al 2001). Therefore, the correct therapeutic approach must be applied to interfere 
with these components. According to Global Initiative for Chronic Obstructive Lung 
Disease Guidelines (GOLD), the main goals of COPD treatment are maintenance of 
improvement in lung function, relief of symptoms, prevention of exacerbations and 
hospitalizations, improvement in quality of life, decrease in accelerated decline in lung 
function, increase in life expectancy, accomplishment of all of these in a cost-effective 
manner, and provision of drugs with minimal side-effects (NHLBI/WHO workshop 
report 2004).
The fixed combination of budesonide–formoterol in a single dry powder 
inhaler (Symbicort® Turbuhaler® [hereafter referred to as budesonide–formoterol]; International journal of COPD 2006:1(2)
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AstraZeneca UK Limited) has been instructed to patients 
with COPD as an alternative to treatment of concurrent 
inhaled corticosteroid and a long-acting β2-agonist, admin-
istered via separate inhalers, or as an alternative to inhaled 
corticosteroids alone (Doherty 2002; Lalloo 2002; Cazzola 
and Dahl 2004; Reynolds et al 2004). This article reviews the 
pharmacology and clinical proﬁ  le of budesonide–formoterol 
in treating patients with COPD.
Pharmacodynamics
The pharmacodynamics of both budesonide and formoterol 
have been documented and reviewed (Bartow and 
Brogden 1998; Boobis 1998; Szeﬂ  er 1999; Hvizdos and 
Jarvis 2000; McGavin et al 2001; Cheer and Scott 2002). 
Budesonide uptake is rapid because of its high afﬁ  nity for 
the glucocorticoid receptor, leading to high initial satura-
tion of the glucocorticoid receptors (Hvizdos and Jarvis 
2000). Reversible esteriﬁ  cation of budesonide on inhalation 
prolongs the duration of action in airways and lung tissue, 
while the moderate lipophilicity of unesteriﬁ  ed budesonide 
limits peripheral tissue retention (Szeﬂ  er 1999; Hvizdos 
and Jarvis 2000; McGavin et al 2001). Budesonide inhibits 
the activities of a wide range of inﬂ  ammatory cells includ-
ing eosinophils, T lymphocytes, mast cells, macrophages, 
dendritic cells, and neutrophils (AstraZeneca 2005). 
Budesonide is widely distributed into tissues; the mean 
volume of distribution at steady state is approximately 
3 L/kg in both children and adults (AstraZeneca 2005). 
At concentrations achieved with recommended dosages, 
85%–90% of the medication binds to plasma proteins 
(AstraZeneca 2005).
Formoterol is a long-acting, selective, β2-agonist bron-
chodilator with a fast onset of action (within 1–3 minutes) 
and a long duration (12 hours) of broncholytic effect. It 
bronchodilates as rapidly as salbutamol (Cazzola et al 2001), 
and its efﬁ  cacy and duration of action are similar to those of 
salmeterol (Cazzola et al 1995). A signiﬁ  cant effect occurs 
with formoterol within minutes of inhalation of a therapeutic 
dose (Faulds et al 1991; Cazzola et al 2004).
Formoterol has also been shown to induce mean peak 
bronchodilation (increase in FEV1 over baseline values) more 
rapidly than salmeterol (Cazzola et al 1995; Aalbers et al 
2002). In addition, Celik et al showed that after 10 minutes, 
formoterol induced a clinically and statistically signiﬁ  cant 
improvement in FEV1 compared with placebo, whereas 
salmeterol required 20 minutes (Celik et al 1999; Johnson 
and Rennard 2001). 
Few data have been published on the pharmacodynamics 
of the combined product in patients with COPD (Fenton and 
Keating 2004; Goldsmith and Keating 2004; AstraZeneca 
2005; GlaxoSmithKline 2005). Formoterol and budesonide 
have demonstrated additive and synergistic effects when 
used in combination. Therefore, budesonide–formoterol 
combination provides an effective treatment option in 
COPD patients (Calverley et al 2003; Szafranski et al 
2003). The concomitant use of a long-acting β2-agonist 
and an inhaled corticosteroid can inﬂ  uence both airway 
obstruction (smooth muscle contraction, increased cholin-
ergic tone, and loss of elastic recoil), and airway inﬂ  am-
mation (increased numbers of neutrophils, macrophages 
and CD8+lymphocytes, elevated IL-8 and TNF-a, and 
protease–antiprotease imbalance) (Cazzola and Dahl 2004; 
Cazzola et al 2004).
A small increase in cortisol suppression was observed 
following administration of budesonide–formoterol com-
pared with the individual components. Nevertheless, this 
increase was not considered clinically relevant (Reynolds 
et al 2004; AstraZeneca 2005).
Pulmonary effects
As mentioned above, budesonide and formoterol have 
demonstrated additive and synergistic effects when used in 
combination. Both lung function and health status of COPD 
patients improved signiﬁ  cantly when patients were treated 
with budesonide–formoterol delivered in a single inhaler 
instead of monotherapy by either budesonide or formoterol 
(Calverley et al 2003; Szafranski et al 2003; Reynolds et al 
2004).
In a double-blind, randomized, crossover study 
in moderate-to-severe COPD patients, inhalations of 
budesonide–formoterol increased FEV1. Budesonide–
formoterol was administered via a Turbuhaler dry powder 
inhaler (Cazzola et al 2003). Budesonide–formoterol 
recipients showed a mean maximum improvement from 
baseline in FEV1 earlier than ﬂ  uticasone–salmeterol recipi-
ents (120 vs 300 minutes; mean maximum improvements of 
0.29 vs 0.32 L). Between-group differences in FEV1 occurred 
at 120 and 360 minutes (Cazzola et al 2003). However, at 
12 hours the mean increase from baseline in FEV1 was the 
same for both combinations (0.10 L) (Cazzola et al 2003). 
Similar results were reported in other 12-month studies 
(Calverley et al 2003; Szafranski et al 2003).
The effects of budesonide–formoterol combination treat-
ment in COPD patients have been investigated. In 2 large, International Journal of COPD 2006:1(2) 117
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12-month, randomized, double-blind, placebo-controlled, 
parallel-group, multicenter trials, moderate-to-severe COPD 
patients received inhalations of budesonide–formoterol 
(160/4.5 μg), budesonide (200 μg) alone, formoterol (4.5 μg) 
alone, or placebo twice daily (Calverley et al 2003; Szafranski 
et al 2003). These studies showed that budesonide–formoterol 
signiﬁ  cantly reduces both the risk of exacerbations and the 
need for medical intervention, and improves lung function 
and decreases symptoms (Calverley et al 2003; Szafranski 
et al 2003).
Anti-inﬂ  ammatory effects
Increasingly, COPD is being recognized as an inﬂ  ammatory 
disorder of both the large and small airways, character-
ized by airway remodeling and emphysematous changes 
in the lung parenchyma (Barnes 2000b). Importantly, the 
severity of airway inﬂ  ammation is directly related to the 
severity of the underlying COPD. In established COPD, 
the peripheral airways show wall inﬂ  ammation, ﬁ  brosis, 
smooth muscle hypertrophy, and goblet cell metaplasia in 
the epithelium, and the airway lumen is often plugged by 
mucus (Casio et al 1978; Xie et al 2003; Scola et al 2004; 
Sin et al 2004).
Formoterol acts by stimulating the adenylate cyclase 
pathways, which, in turn, increases intracellular concentra-
tions of cyclic adenosine monophosphate (Scola et al 2004). 
Although formoterol, itself has weak anti-inﬂ  ammatory 
effect, in vitro studies suggest that it can materially amplify 
the effects of budesonide when administered in combination 
therapy, making it possible to achieve large anti-inﬂ  ammatory 
effects even with relatively low doses of budesonide. Formot-
erol also appears to increase the effectiveness of budesonide 
in suppressing expression of adhesion molecules such as 
intercellular adhesion molecule-1. The bronchodilatory 
effect of formoterol may also facilitate budesonide deposi-
tion into areas of the lung, wherein active inﬂ  ammation is 
present and prominent. Furthermore long-acting β2-agonists 
enhance nuclear localization of glucocorticoid receptors and 
suppression of inﬂ  ammatory mediators by corticosteroids 
(Sin et al 2004).
Corticosteroids attenuate neutrophil recruitment activa-
tion, and chemotaxis (Lomas et al 1991; Llewellyn-Jones et 
al 1994). Moreover, they reduce the numbers of mucosal and 
subepithelial mast cells, and reduce the epithelial CD8/CD4 
ratio, although they have no effect on the major inﬂ  amma-
tory cell types in COPD (Gizycki et al 2002; Hattotuwa 
et al 2002). Inhaled corticosteroids (ICS) also signiﬁ  cantly 
reduce bronchoalveolar lavage fluid levels of IL-8 and 
myeloperoxidase, and also cell numbers, and reduce the pro-
portion of neutrophils, symptom score, and bronchitis index 
(Balbi et al 2000). These ﬁ  ndings seem to support the use 
of ICS in treating COPD, although long-term treatment with 
ICS must be associated with a high risk of adverse systemic 
effects and involves unnecessary expense (Barnes 2000a).
In vivo studies have demonstrated that combined usage 
of formoterol and budesonide produces a greater effect on 
airway inﬂ  ammation than either drug alone with a comple-
mentary interaction (Sin et al 2004).
Pharmacokinetics
The pharmacokinetics of inhaled forms of both budesonide 
and formoterol have previously been reviewed in detail 
(Bartow and Brogden 1998; Boobis 1998; Edsbäcker 1999; 
Donnelly and Seal 2001; Cheer and Scott 2002).
Data on combination budesonide–formoterol other than 
the one present in the manufacturer’s summary are difﬁ  cult 
to ﬁ  nd (AstraZeneca 2005). In this study, the mean lung 
deposition of budesonide after inhalation via a Turbuhaler 
device was reported as 32%–44% of the delivered dose 
and the amount of formoterol that reaches the lungs from a 
Turbuhaler was reported as 28%–49% of the delivered dose 
(AstraZeneca 2005). The pharmacokinetics of the individual 
components are brieﬂ  y described below.
Absorption and distribution
Following inhalation, budesonide fatty acid esteriﬁ  cation 
in the airways (Edsbäcker and Brattsand 2002) rapidly 
dissolves in bronchial secretions (Edsbäcker 1999). It was 
concluded that budesonide reaches maximum plasma con-
centration (Cmax) at 17–30 minutes (Thorsson et al 1994; 
Edsbäcker 1999; Donnelly and Seal 2001; AstraZeneca 
2005). The budesonide–formoterol Turbuhaler delivers half 
of the labeled dose as ﬁ  ne particles. The systemic bioavail-
ability of budesonide is nearly half of the delivered dose 
(AstraZeneca 2005).
Following inhalation, absorption of inhaled formoterol is 
rapid and reaches maximum Cmax at 10 minutes. Its systemic 
bioavailability is approximately 61% of the delivered dose 
(AstraZeneca 2005).
Therapeutic efﬁ  cacy
The effects of budesonide–formoterol combination treatment 
via Turbuhaler in COPD patients also have been investigated. International journal of COPD 2006:1(2)
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This section reviews studies assessing the efficacy of 
budesonide–formoterol combination as maintenance therapy 
with COPD and the effect of this combination on health-related 
quality of life (HRQL) (Calverley et al 2003; Szafranski et al 
2003; Cazzola et al 2004).
The efﬁ  cacy of budesonide–formoterol in COPD patients 
has been studied in 2 large, 12-month, randomized, double-
blind, placebo-controlled, parallel-groups, multicenter clini-
cal trials. These studies showed that budesonide–formoterol 
signiﬁ  cantly reduces both the risk of exacerbations and the 
need for medical intervention, and provides rapid, sustained 
improvement in lung function and symptom relief (Calverley 
et al 2003; Szafranski et al 2003).
In the study of Calverley et al, 1022 patients (mean age, 
64 years; FEV1, 0.98 L and 36% predicted) with severe COPD 
(FEV1 < 50% predicted normal) and a history of exacerba-
tions were included. Initially, treatment was intensiﬁ  ed with 
the oral steroid prednisolone (30 mg once daily) and inhaled 
formoterol Turbuhaler (4.5 μg twice daily) for 2 weeks, in 
an attempt to optimize patients’ health status. Following the 
intensiﬁ  cation period, patients were randomized to receive 
budesonide–formoterol Turbuhaler (160/4.5 μg, twice daily), 
budesonide Turbuhaler alone (200 μg, twice daily), formot-
erol Turbuhaler alone (4.5 μg, twice daily), or placebo for 
1 year (Calverley et al 2003).
The study of Szafranski et al involved 812 patients 
(mean age, 64 years; FEV1, 0.96 L and 36% predicted) 
with severe COPD (FEV1 < 50% predicted normal) and a 
history of exacerbations. Patients were randomized to re-
ceive budesonide–formoterol Turbuhaler (160/4.5 μg, twice 
daily), budesonide Turbuhaler alone (200 μg, twice daily), 
formoterol Turbuhaler alone (4.5 μg, twice daily), or placebo 
for 1 year, after a 2-week run-in period when maintenance 
medication was withdrawn and only terbutaline was allowed 
as rescue (Szafranski et al 2003).
Effect on lung function
Budesonide–formoterol combination therapy provides a rapid 
and sustained improvement in lung function (Calverley et al 
2003; Szafranski et al 2003). Calverley et al (2003) showed 
that budesonide–formoterol therapy was signiﬁ  cantly better 
than that with long-acting β2-agonists alone, corticosteroids 
alone, or placebo in maintaining the lung function improve-
ment achieved after optimization. Mean FEV1 values in the 
budesonide–formoterol group remained 14%, 11%, and 5% 
above the values in the placebo group, budesonide group, 
and formoterol group, respectively (Figure 1). Morning 
peak expiratory ﬂ  ow (PEF) in the budesonide–formoterol 
group was 18 L/minute, 15 L/minute, and 7 L/minute above 
the value in the placebo group, budesonide group, and 
formoterol group, respectively. The value for evening PEF 
in the budesonide–formoterol group was 14 L/minute, 
12 L/minute, and 5 L/minute above the value in the placebo 
group, budesonide group, and formoterol group, respectively. 
Forced vital capacity value in the budesonide–formoterol 
group was 9%, 8%, and 2% above that in the placebo group, 
budesonide group, and formoterol group, respectively 
(Calverley et al 2003).
Szafranski et al (2003) reported that at trial endpoint, 
patients receiving budesonide–formoterol had FEV1 values 
15%, 9%, and 1% greater than those receiving placebo, 
budesonide recipients, and formoterol alone, respectively. 
Mean FEV1 values at baseline across treatment groups 
ranged from 0.96 to 1.01 L. These lung function improve-
ments were maintained throughout the 12-month study. 
Signiﬁ  cant improvements in morning and evening PEF 
values were observed during the 12 months of therapy with 
budesonide–formoterol compared with all other treatment 
groups (adjusted mean change from run-in: morning PEF, 
24, 16, and 12 L/min vs placebo, budesonide alone, and 
formoterol alone, respectively; evening PEF, 20, 15, and 
11 L/min vs placebo, budesonide alone, and formoterol alone, 
respectively) (Szafranski et al 2003).
Figure 1 Changes in mean FEV1 in the 4 treatment groups from randomisation to 
the average of all available measurements during the 12-month treatment period. 
Budesonide–formoterol (■) vs budesonide ( ), p < 0.001; budesonide–formoterol 
vs formoterol ( ), p = 0.002; budesonide vs placebo ( ), p = 0.145; formoterol vs 
placebo, p < 0.001; budesonide–formoterol vs placebo, p < 0.001. Reprinted from 
Calverley PM, Boonsawat Z, Zhong N, et al. 2003. Maintenance therapy with 
budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 
22:912–9. Copyright © 2003, with permission from European Respiratory Society 
Journals Ltd.
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In a double-blind, randomized, crossover study 
in moderate-to-severe COPD patients, inhalations of 
budesonide–formoterol increased FEV1. Budesonide–
formoterol was administered via a Turbuhaler dry powder 
inhaler (Cazzola et al 2003). Budesonide–formoterol recipi-
ents showed a mean maximum improvement from baseline 
in FEV1 earlier than ﬂ  uticasone–salmeterol recipients (120 vs 
300 minutes; mean maximum improvements of 0.29 vs 
0.32 L). Between-group differences in FEV1 occurred at 
120 and 360 minutes, but at 12 hours the mean increase 
from baseline in FEV1 was the same for both combinations 
(0.10 L) (Cazzola et al 2003). Similar results were reported 
in other 12-month studies (Calverley et al 2003; Szafranski 
et al 2003).
Effect on COPD symptoms
Budesonide–formoterol combination therapy provides 
significantly greater reduction in the symptoms of 
COPD. The improvement in lung function observed after 
budesonide–formoterol treatment must be considered to be 
important, but the greater capacity of budesonide–formoterol 
to decrease the mean total symptom score (night-time 
awakenings, shortness of breath, cough, and chest tight-
ness), to increase the number of days free from shortness 
of breath by 12% vs placebo, and to increase the number of 
awakening-free nights by 14% vs placebo, each of which 
is equivalent to approximately 1 extra day/night per week, 
is likely to have a substantial impact on health (Szafranski 
et al 2003). This effect was sustained for 12 months for 
budesonide–formoterol vs placebo and budesonide alone 
(Calverley et al 2003; Szafranski et al 2003).
The reduction in shortness of breath score was signiﬁ  -
cantly greater in patients receiving budesonide–formoterol 
than in those receiving budesonide, an improvement 
that was sustained throughout the 12-month study 
period without any signs of tachyphylaxis (Calverley 
et al 2003).
Exacerbations of COPD
In addition to physical deterioration, COPD exacerbations 
have a major impact on patients’ feelings of well-being and 
HRQL, and are extremely distressing for patients (Donaldson 
et al 2002). As the disease worsens, patients ﬁ  nd it increas-
ingly difﬁ  cult to perform even the activities of everyday 
living. Patients who have exacerbations more frequently have 
a worse HRQL (Seemungal et al 1998).
Budesonide–formoterol combination therapy was shown 
to signiﬁ  cantly reduce exacerbations vs formoterol alone 
and placebo. Budesonide–formoterol has been shown to 
extend the time interval to ﬁ  rst severe exacerbation by 158, 
100, and 76 days more than placebo, formoterol alone, 
and budesonide alone, respectively (Calverley et al 2003). 
Szafranski et al (2003) reported that budesonide–formoterol 
extended the time interval to ﬁ  rst severe exacerbation by 156, 
100, and 76 days more than placebo, formoterol alone, and 
budesonide alone, respectively. These reductions in exacerba-
tions provide a signiﬁ  cant improvement in COPD patients’ 
quality of life, and give patients the conﬁ  dence to return to 
everyday activities. Budesonide–formoterol therapy also 
reduced the risk of exacerbation by 29%, 30%, and 23% vs 
placebo, formoterol alone, and budesonide alone, respectively 
(Calverley et al 2003). Budesonide–formoterol was seen to 
reduce the risk of exacerbations by 23%, 24%, and 11% vs 
placebo, formoterol alone, and budesonide alone, respectively 
(Szafranski et al 2003).
Effect on HRQL
The HRQL of patients with COPD can be measured using 
the St. George’s Respiratory Questionnaire (SGRQ), which 
measures the impact of the disease on well-being and daily 
life, and has been validated for use in patients with COPD 
(Jones 1992). A reduction in score of 4 is considered a 
clinically relevant improvement, noticeable by the patient. 
A worse quality of life predicts a worse clinical outcome 
(Osman et al 1997).
Adding inhaled corticosteroids to the treatment has 
been shown to signiﬁ  cantly improve HRQL in patients 
with COPD (Yildiz et al 2004). Budesonide–formoterol 
has been shown to provide a meaningful improvement in 
COPD patients’ HRQL (Calverley et al 2003; Szafranski 
et al 2003). Szafranski et al (2003) reported that the reduction 
from baseline in mean SGRQ total score was signiﬁ  cantly 
greater in patients treated with budesonide–formoterol than 
in placebo recipients (–3.9 vs –0.03 units). In patients re-
ceiving budesonide–formoterol, the SGRQ symptom and 
impact scores were reduced by 5.9 and 4.7 units more than 
the reduction in the SGRQ symptom and impact scores in 
placebo recipients. Mean reductions from baseline in the 
SGRQ total score were –1.9 and –3.6 units in budesonide 
and formoterol recipients, respectively. SGRQ total scores at 
baseline, before which patients received rescue-medication 
only, ranged from 51 to 54 in the 4 groups.International journal of COPD 2006:1(2)
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Calverley et al (2003) reported that budesonide–
formoterol combination therapy provided a sustained reduc-
tion of –7.5 in SGRQ score, compared with the reduction in 
SGRQ score in placebo, a superior improvement to that seen 
with formoterol alone (reduction of –4.1 vs placebo) and 
budesonide alone (reduction of –3.0 vs placebo). Budeso-
nide–formoterol improved SGRQ scores signiﬁ  cantly when 
compared with budesonide and formoterol alone, by 4.5 and 
3.4 units, respectively.
Tolerability
Budesonide–formoterol combination therapy is well 
tolerated in COPD patients and shows a similar frequency 
of adverse events when compared with budesonide alone 
and formoterol alone. The adverse effects of inhaled 
budesonide (Pauwels et al 1999; Johnell et al 2002) and 
formoterol (Cheer and Scott 2002; Dahl et al 2002) in 
patients with COPD have been described in detail else-
where. Tolerability data have also been previously reported 
(Calverley et al 2003; Szafranski et al 2003; AstraZeneca 
2005).
Budesonide–formoterol combination therapy was gener-
ally well tolerated in patients with COPD. Statistical analysis 
of tolerability data was reported for withdrawal rates only 
(Szafranski et al 2003) (Figure 2).
Calverley et al (2003) reported the withdrawal of 393 of 
1022 randomized patients (38%), 193 because of deteriora-
tion of COPD. Szafranski et al (2003) reported the withdrawal 
of 275 of 812 randomized patients (34%), 115 because of 
deterioration of COPD. In both trials, a signiﬁ  cantly higher 
number of withdrawals due to deterioration of COPD oc-
curred in the placebo groups (23% and 21%) compared 
with the budesonide–formoterol groups (11% and 10%). A 
signiﬁ  cantly smaller proportion of patients withdrew from 
the budesonide–formoterol group due to deterioration of 
COPD than from the budesonide (18%; p = 0.038) or formot-
erol (23%; p < 0.001) groups in the larger study (Calverley 
et al 2003).
Adverse effects of the combination of budesonide–
formoterol in a double-blind, randomized trial with COPD 
were respiratory infection (14%), pneumonia (3%), 
pharyngitis (3%), fever (2%), dyspnea worsening (2%), 
chest pain (3%), back pain (3%), diysphonia (2%), rhinitis 
(4%), hypertension (2%), and moniliazis (2%) (Calverley 
et al 2003).
Fewer patients withdrew from the study in the budeso-
nide–formoterol group than in the budesonide alone, formot-
erol alone, or placebo groups (Calverley et al 2003).
Dosage and administration
One inhalation twice daily of budesonide–formoterol 
200/6 μg and 400/12 μg via the Turbuhaler device is ap-
proved in many countries for the symptomatic treatment of 
patients with severe COPD (FEV1 < 50% predicted normal) 
and a history of repeated exacerbations who have signiﬁ  cant 
symptoms despite regular therapy with long-acting bron-
chodilators (AstraZeneca 2005). The budesonide–formot-
erol 200/6 μg inhaler delivers 160 μg of budesonide and 
4.5 μg of formoterol per dose; the 400/12 μg inhaler delivers 
320 μg of budesonide and 9 μg of formoterol per dose. The 
recommended dosage for the treatment of COPD in adults 
is 320/9 μg twice daily (AstraZeneca 2005). Formoterol is 
a long-acting bronchodilator and should not be used for 
rescue medication. In elderly patients dosage adjustment is 
not required (AstraZeneca 2005).
Budesonide–formoterol: current 
status
Budesonide–formoterol combination therapy administered 
via the Turbuhaler dry powder inhaler is currently approved 
in many countries for the treatment of patients with severe 
COPD. The recommended dosage of the drug is 320/9 μg 
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Figure 2 Kaplan-Meier plot of discontinuations, by treatment group. 
–– Symbicort; ..... budesonide; ----- formoterol; –..– placebo. Reprinted from 
Szafranski W, Cukier A, Ramirez A, et al. 2003. Efﬁ  cacy and safety of budeso-
nide–formoterol in the management of chronic obstructive pulmonary disease. Eur 
Respir J, 21:74–81. Copyright © 2003, with permission from European Respiratory 
Society Journals Ltd.International Journal of COPD 2006:1(2) 121
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twice a day. In clinical trials with COPD, combined 
budesonide–formoterol administered via the Turbuhaler 
dry powder inhaler has proven more effective in improving 
lung function and reducing exacerbations when compared 
with the same dose of budesonide or formoterol given alone. 
Budesonide–formoterol combination therapy is also safer 
and tolerated better than the same dose of budesonide or 
formoterol given alone.
References
Aalbers R, Ayres J, Backer V, et al. 2002. Formoterol in patients with chronic 
obstructive pulmonary disease: a randomized, controlled, 3-month trial. 
Eur Respir J, 19:936–43.
AstraZeneca UK Limited. 2005. Symbicort® Turbuhaler® summary of 
product characteristics [online]. Accessed 20 August 2005. URL: 
http://emc.medicines.org.uk.
Balbi B, Majori M, Bertacco S, et al. 2000. Inhaled corticosteroids in stable 
COPD patients: do they have effects on cells and molecular mediators 
of airway inﬂ  ammation? Chest, 117:1633–7.
Barnes PJ. 2000a. Inhaled corticosteroids are not beneﬁ  cial in chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med, 161:342–4.
Barnes PJ. 2000b. Chronic obstructive pulmonary disease. Review. N Engl 
J Med, 343:269–80.
Bartow RA, Brogden RN. 1998. Formoterol: an update of its pharmacologi-
cal properties and therapeutic efﬁ  cacy in the management of asthma. 
Drugs, 2:303–22.
Boobis A. 1998. Comparative physiochemical and pharmacokinetic proﬁ  les 
of inhaled beclomethasone dipropionate and budesonide. Respir Med, 
92(Suppl B):2–6.
Calverley PM, Boonsawat Z, Zhong N, et al. 2003. Maintenance therapy with 
budesonide and formoterol in chronic obstructive pulmonary disease. 
Eur Respir J, 22:912–9.
Casio M, Ghezzo H, Hogg JC, et al. 1978. The relations between structural 
changes in small airways and pulmonary function tests. N Eng J Med, 
298:1277–81.
Cazzola M, Centanni S, Regorda C, et al. 2001. Onset of action of single 
doses of formoterol administered via Turbuhaler in patients with stable 
COPD. Pulm Pharmacol Ther, 14:41–5.
Cazzola M, Dahl R. 2004. Inhaled combination therapy with long-
acting β2-agonists and corticosteroids in stable COPD. Chest, 
126:220–37.
Cazzola M, Matera MG, Santangelo G, et al. 1995. Salmeterol and formot-
erol in partially reversible severe chronic obstructive pulmonary disease: 
a dose-response study. Respir Med, 89:357–62.
Cazzola M, Santus P, Di Marco F, et al. 2003. Bronchodilator effect of an 
inhaled combination therapy with salmeterol + ﬂ  uticasone and formoterol 
+ budesonide in patients with COPD. Respir Med, 97:453–7.
Cazzola M, Santus P, Di Marco F, et al. 2004. Onset of action of formot-
erol/budesonide in single inhaler vs. formoterol in patients with COPD. 
Pulm Pharmacol Ther, 17: 121–5.
Celik G, Kayacan O, Beder S, et al. 1999. Formoterol and salmeterol in 
partially reversible chronic obstructive pulmonary disease: a crosso-
ver, placebo-controlled comparison of onset and duration of action. 
Respiration, 66:434–9.
Cheer SM, Scott LJ. 2002. Formoterol: a review of its use in chronic obstruc-
tive pulmonary disease. Am J Respir Med, 1:285–300.
Dahl R, Kristufek P, Greefhorst APM, et al. 2000. The cardiac safety proﬁ  le 
of formoterol dry powder is similar to placebo in patients with COPD 
[Abstract]. Eur Respir J, 16(Suppl 31):51s, P497.
Doherty DE. 2002. Early detection and management of COPD. What you 
can do to reduce the impact of this disabling disease. Postgrad Med, 
111:41–4.
Donaldson GC, Seemungal TAR, Bhowmik A, et al. 2002. Relationship 
between exacerbation frequency and lung function decline in chronic 
obstructive pulmonary disease. Thorax, 57:847–52.
Donnelly R, Seal JP. 2001. Clinical pharmacokinetics of inhaled budesonide. 
Clin Pharmacokinet, 40:427–40.
Edsbäcker S. 1999. Pharmacological factors that inﬂ  uence the choice of 
inhaled corticosteroids. Drugs, 58(Suppl 4):7–16.
Edsbäcker S, Brattsand R. 2002. Budesonide fatty-acid esteriﬁ  cation: a novel 
mechanism prolonging binding to airway tissue. Review of available 
data. Ann Allergy Asthma Immunol, 88:609–16.
Fabbri LM, Hurd SS. For the GOLD Scientiﬁ  c Committee. 2003. Global 
strategy for the diagnosis, management and prevention of COPD. Eur 
Respir J, 22:1–2.
Faulds D, Hollingshead LM, Goa KL. 1991. Formoterol. A review of its 
pharmacological properties and therapeutic potential in reversible 
obstructive airways disease. Drugs, 42:115–37.
Fenton C, Keating GM. 2004. Inhaled salmeterol/ﬂ  uticasone propionate: 
a review of its use in chronic obstructive pulmonary disease. Drugs, 
64:1975–96.
GlaxoSmithKline. 2005. Advair Diskus 100/50 250/50 500/50 Prescribing 
Information [online]. Accessed 25 August 2005. URL: http://www.gsk.
com/products/advair_us.htm.
Gizycki MJ, Hattotuwa KL, Barnes N, et al. 2002. Effects of ﬂ  uticasone 
propionate on inﬂ  ammatory cells in COPD: an ultrastructural examina-
tion of endobronchial biopsy tissue. Thorax, 57:799–803.
Goldsmith DR, Keating GM. 2004. Budesonide–formoterol: a review of its 
use in asthma. Drugs, 64:1597–618.
Hattotuwa KL, Gizycki MJ, Ansari TW, et al. 2002. The effects of inhaled 
ﬂ  uticasone on airway inﬂ  ammation in chronic obstructive pulmonary 
disease: a double-blind, placebocontrolled biopsy study. Am J Respir 
Crit Care Med, 165:1592–6.
Hvizdos KM, Jarvis B. 2000. Budesonide inhalation suspension: a review 
of its use in infants, children and adults with inﬂ  ammatory respiratory 
disorders. Drugs, 60:1–38.
Johnell O, Pauwels R, Löfdahl C-G, et al. 2002. Bone mineral density 
in patient with chronic obstructive pulmonary disease treated with 
budesonide Turbuhaler®. Eur Respir J, 19:1058–63.
Johnson M, Rennard S. 2001. Alternative mechanisms for long acting β2-
adrenergic agonists in COPD. Chest, 120:258–70.
Jones PW, Quirk FH, Baveystock CM, et al. 1992. A self-complete meas-
ure of health status for chronic airﬂ  ow limitation. Am Rev Respir Dis, 
145:1321–7.
Lalloo U. 2002. Symbicort®: controlling asthma in adults. Respir Med, 
96(Suppl A):16–22.
Llewellyn-Jones CG, Hill SL, Stockley RA. 1994. Effect of ﬂ  uticasone 
propionate on neutrophil chemotaxis, superoxide generation, and ex-
tracellular proteolytic activity in vitro. Thorax, 49:207–12.
Lomas DA, Ip M, Chamba A, et al. 1991. The effect of in vitro and in 
vivo dexamethasone on human neutrophil function. Agents Actions, 
33:279–85.
McGavin JK, Goa KL, Jarvis B. 2001. Inhaled budesonide–formoterol 
combination. Drugs, 61:71–8.
NHLBI/WHO. 2004. Global Initiative for Chronic Obstructive Lung Dis-
ease. Global Strategy for the Diagnosis, Management, and Prevention 
of Chronic Obstructive Lung Disease. National Heart, Lung and Blood 
Institute. Update of the management sections [online]. Accessed July 
2004. URL: http://www.goldcopd.com.
Osman LM, Godden DJ, Friend JAR, et al. 1997. Douglas JG. Quality 
of life and hospital re-admission in patients with chronic obstructive 
pulmonary disease. Thorax, 52:67–71.
Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmo-
nary disease: NHLBI/WHO Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) workshop summary. Am J Respir Crit Care 
Med, 163:1256–76.International journal of COPD 2006:1(2)
Ceylan
122
Pauwels RA, Löfdahl CG, Laitinen LA, et al. 1999. Long-term treatment 
with inhaled budesonide in persons with mild chronic obstructive 
pulmonary disease who continue smoking: European Respiratory 
Society Study on Chronic Obstructive Pulmonary Disease. N Engl J 
Med, 340:1948–53
Reynolds NA, Perry CM, Keating GM. 2004. Budesonide–formoterol in 
chronic obstructive pulmonary disease. Drugs, 64:431–41.
Scola AM, Chong LK, Suvama SK, et al. 2004. Desensitization of mast cell 
beta2-adrenoceptor-mediated responses by salmeterol and formoterol. 
Br J Pharmacol, 141:163–71.
Seemungal TAR, Donaldson GC, Paul EA, et al. 1998. Effect of exacerba-
tion on quality of life in patients with chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med, 157:1418–22.
Sin DD, Johnson M, Qi Gan W, et al. 2004. Paul Man SF. Combination 
therapy of inhaled corticosteroids and long-acting β2-adrenergic in 
management of patients with chronic obstructive lung disease. Curr 
Pharm Des, 10:3547–60.
Szafranski W, Cukier A, Ramirez A, et al. 2003. Efﬁ  cacy and safety of 
budesonide–formoterol in the management of chronic obstructive 
pulmonary disease. Eur Respir J, 21:74–81.
Szefler SJ. 1999. Pharmacodynamics and pharmacokinetics of 
budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol, 
104: S175–83.
Thorsson L, Edsbäcker S, Conradson T-B. 1994. Lung deposition of budeso-
nide from Turbuhaler is twice that from a pressurized metered-dose 
inhaler P-MDI. Eur Respir J, 7:1839–44.
Xie QM, Chen JQ, Shen WH, et al. 2003. Comparison of bronchodilat-
ing and antiinﬂ  ammatory activities of oral formoterol and its (R,R)-
enantiomersl. Acta Pharmacol Sin, 24:277–82.
Yildiz F, Basyigit I, Yildirim E, et al. 2004. Does addition of inhaled steroid 
to combined bronchodilator therapy affect health status in patients with 
COPD? Respirology, 9:352–5.